Stentys has announced that the first interventions using its self-expanding drug-eluting stent to treat BTK (below-the-knee) arterial disease have been performed during two live-case sessions broadcasted during the Leipzig Interventional Course (LINC).
The two procedures on patients suffering from critical lower-limb ischaemia (CLI) were performed by the Leipzig University Hospital angiology team (Andrej Schmidt, Sven Bräunlich, Matthias Ulrich). Several overlapping Stentys stents were successfully implanted to treat the long lesions of the leg arteries.
Gonzague Issenmann, chief executive officer and co-founder of Stentys, comments, “These first two procedures outside of a clinical trial went perfectly well, and the final results were unanimously acclaimed by the members of the panel of experts who moderated the cases. The physicians were delighted to learn that they can now treat their patients with a drug-eluting and self-expanding stent, the first available for this indication in Europe.”